Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-08-17
1999-06-01
MacMillan, Keith
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514946, 514947, 514817, A61K 31485, A61K 4700, A61K 970
Patent
active
059088460
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the use of prodrug derivatives of morphine in effecting transdermal delivery of morphine to the systemic circulation of a mammal.
For purposes of this specification, the term "prodrug" denotes a derivative of morphine which, when administered topically to warm-blooded animals, e.g. humans, is converted into the proven drug, i.e. morphine.
The prodrug forms of morphine of this invention are certain derivatives of morphine which possess a desirable high lipophilicity and biphasic solubility in comparison to the parent compound, morphine, and which are cleaved enzymatically to morphine.
2. Description of the Prior Art
It is generally known and an accepted practice to administer morphine to control chronic pain. Morphine plays a prominent role in the control of pain associated with chronic diseases, especially the chronic pain of cancer, and acute pain, especially the acute pain experienced post-operatively. However, such prior art uses of morphine are subject to serious problems. In addition to the obvious problems associated with potential abuse and addiction, the oral and parenteral administration of morphine for pain control frequently involve wide swings in the pharmacodynamics of the drug over each dosing interval. Furthermore, morphine has a short duration of action and is inefficiently and variably absorbed orally due to first-pass metabolism in the intestine and liver.
During recent years much attention has been paid to the development of transdermal delivery systems as a means of mitigating many of the drawbacks associated with the parenteral or oral route of administration. (Sloan K B, Adv. Drug Delivery Rev. (1989), 67-101) A prerequisite for the development of a transdermal delivery system of morphine and other opioids is, however, that the drugs are capable of penetrating the skin at a sufficiently high rate and are not metabolized during the percutaneous absorption. Morphine which remains the analgesic drug of choice for the treatment of severe pain, unfortunately exhibits, a very limited skin permeability which makes it unsuited for transdermal delivery. For instance, the steady-state flux of morphine through human skin in vitro has been reported to be only 6 ng/cm.sup.2 /h when applied in the form of a saturated solution (pH 7.4). (Roy, S. D., and Flynn, G. L., Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin Pharm. Res. 6 (1989) 825-832). These poor skin-penetration properties of morphine led to the conclusion that morphine is totally unsuited for transdermal delivery. The very poor ability of morphine to permeate into and through the skin can mainly be ascribed to its poor lipophilicity. Thus, the log P value for morphine is only -0.15 where P is the partition coefficient between octanol and aqueous buffer of pH 7.4 (Roy and Flynn 1989). It has now surprisingly been found that transdermal delivery of morphine can be achieved by the prodrug approach proposed in accordance with the present invention.
SUMMARY OF THE INVENTION
The present invention provides novel topical compositions for transdermal delivery comprising an effective amount of a compound represented by the following general Formula I ##STR1## where R.sub.1 and R.sub.2 are the same or different and are hydrogen and a member selected from the group of physiologically hydrolyzable chemical groups consisting of alkylcarbonyl, alkenylcarbonyl arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl and heteroaryloxycarbonyl groups wherein the alkyl moiety consists of unsubstituted or substituted, straight-chain and branched-chain and cyclic alkyl groups having 1-20 carbon atoms, wherein the alkenyl moiety consists of unsubstituted and substituted, straight-chain and branched-chain and cyclic alkenyl groups having 2-20 carbon atoms, wherein the aryl moiety consists of unsubstituted and substituted phenyl, and phenalkyl groups wherein the alkyl moiety contains 1-3 car
REFERENCES:
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4879297 (1989-11-01), Mahjour et al.
patent: 4891377 (1990-01-01), Shipman, Jr. et al.
patent: 4908389 (1990-03-01), Mahjour et al.
patent: 4940586 (1990-07-01), Cheng et al.
patent: 5240932 (1993-08-01), Morimoto et al.
Roy, et al., Transdermal Delivery of Narcotic Analgesics: Comparative Permeabilities of Narcotic Analgesics Through Human Cadaver Skin, Pharmaceutical Research, vol. 6, No. 10 (1989), pp. 825-832.
Rieg-Falson, et al., Characterization of the Enhancing Effect of a Vehicle in a Transdermal System, Drug Development and Industrial Pharmacy, 15(14-16) (1989), pp. 2393-2406.
Sloan, Prodrugs for dermal delivery, Advanced Drug Delivery Reviews, vol. 3. (1989), pp. 67-101.
Rieg-Falson, et al., Characterization of the Enhancing Effect of a Vehicle in a Transdermal System, Drug Development and Industrial (Chm./Abs.), Pharmaceuticals, vol. 112, No. 63 (1990), p. 433.
CA 103:42702 Jane, I, et al, "High-performance liquid chromatographic analysis of basic drugs on silica columns using non-aqueous ionic elements,". J. Chromatogr (1985), 323(3), 191-225. Abstract only.
CA 109:48344, Brockkamp et al, "Prodrug behavior of nicotinoyl-morphine derivatives", J. Pharm. Pharmacol. (1988), 40(6), 434-7. Abstract only.
Bundgaard, deceased Hans
Christrup Lona
Drustrup Jorn
Fullerton Ann
Nicklasson Martin
MacMillan Keith
Pharmacia & UpJohn AB
LandOfFree
Topical compositions for transdermal delivery of prodrug derivat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical compositions for transdermal delivery of prodrug derivat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical compositions for transdermal delivery of prodrug derivat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-955090